RADLY Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of 1.63% compared to Raia Drogasil SA's net margin of --. Raia Drogasil SA's return on equity of 18.54% beat CEL-SCI's return on equity of --.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 6699.55%. Given that CEL-SCI has higher upside potential than Raia Drogasil SA, analysts believe CEL-SCI is more attractive than Raia Drogasil SA.

Raia Drogasil SA has a beta of 0.163, which suggesting that the stock is 83.749% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

Raia Drogasil SA has a quarterly dividend of $0.01 per share corresponding to a yield of 2.5%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raia Drogasil SA pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Raia Drogasil SA quarterly revenues are $1.7B, which are larger than CEL-SCI quarterly revenues of --. Raia Drogasil SA's net income of $28M is higher than CEL-SCI's net income of -$6.6M. Notably, Raia Drogasil SA's price-to-earnings ratio is 21.92x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 0.57x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Hypera SA has a net margin of 1.63% compared to Raia Drogasil SA's net margin of -12.95%. Raia Drogasil SA's return on equity of 18.54% beat Hypera SA's return on equity of 7.07%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Hypera SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Raia Drogasil SA has higher upside potential than Hypera SA, analysts believe Raia Drogasil SA is more attractive than Hypera SA.

Raia Drogasil SA has a beta of 0.163, which suggesting that the stock is 83.749% less volatile than S&P 500. In comparison Hypera SA has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.793%.

Raia Drogasil SA has a quarterly dividend of $0.01 per share corresponding to a yield of 2.5%. Hypera SA offers a yield of 4.08% to investors and pays a quarterly dividend of $0.05 per share. Raia Drogasil SA pays -- of its earnings as a dividend. Hypera SA pays out 58.71% of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Raia Drogasil SA quarterly revenues are $1.7B, which are larger than Hypera SA quarterly revenues of $184.4M. Raia Drogasil SA's net income of $28M is higher than Hypera SA's net income of -$23.9M. Notably, Raia Drogasil SA's price-to-earnings ratio is 21.92x while Hypera SA's PE ratio is 21.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 0.57x versus 2.64x for Hypera SA. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of 1.63% compared to Raia Drogasil SA's net margin of -711.67%. Raia Drogasil SA's return on equity of 18.54% beat IGC Pharma's return on equity of -116.24%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1059.83%. Given that IGC Pharma has higher upside potential than Raia Drogasil SA, analysts believe IGC Pharma is more attractive than Raia Drogasil SA.

Raia Drogasil SA has a beta of 0.163, which suggesting that the stock is 83.749% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

Raia Drogasil SA has a quarterly dividend of $0.01 per share corresponding to a yield of 2.5%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raia Drogasil SA pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Raia Drogasil SA quarterly revenues are $1.7B, which are larger than IGC Pharma quarterly revenues of $257K. Raia Drogasil SA's net income of $28M is higher than IGC Pharma's net income of -$1.8M. Notably, Raia Drogasil SA's price-to-earnings ratio is 21.92x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 0.57x versus 20.11x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 1.63% compared to Raia Drogasil SA's net margin of -49.65%. Raia Drogasil SA's return on equity of 18.54% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Raia Drogasil SA has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that NovaBay Pharmaceuticals has higher upside potential than Raia Drogasil SA, analysts believe NovaBay Pharmaceuticals is more attractive than Raia Drogasil SA.

Raia Drogasil SA has a beta of 0.163, which suggesting that the stock is 83.749% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Raia Drogasil SA has a quarterly dividend of $0.01 per share corresponding to a yield of 2.5%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Raia Drogasil SA pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Raia Drogasil SA quarterly revenues are $1.7B, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Raia Drogasil SA's net income of $28M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Raia Drogasil SA's price-to-earnings ratio is 21.92x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Raia Drogasil SA is 0.57x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.